SITE015-0079

SITE015 (POL) › SITE015-0079

SITE015-0079

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE015 (POL) · Dr. Ito
consented 2025-12-01

enrolled

AEs

5

Serious

1

Dropout signal

–

Adverse events

5

Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-02-14 (study day 255); relationship: NOT RELATED

moderate assessed

Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-01-05 (study day 215); relationship: RELATED

moderate assessed

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-12-13 (study day 192); relationship: RELATED

mild assessed

Grade 4 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2022-09-26 (study day 114); relationship: not assessed; serious criteria: life-threatening

severe serious assessed

Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2022-09-09 (study day 97); relationship: RELATED

moderate assessed

Data queries

0

No data queries. Open queries would appear here for this patient.